Phospholipase A2 enzymes PLA2G2A and PLA2G12B as potential diagnostic and prognostic biomarkers in cholangiocarcinoma

Figure 5 Expression and diagnostic potential of PLA2G2A, PLA2G12B, and microRNAs in cholangiocarcinoma and related conditions. A and B: Expression of PLA2G2A, PLA2G12B in serum and urine. Intrahepatic cholangiocarcinoma (ICC), primary sclerosing cholangitis (PSC), and non-tumor (N); C: The differentially expressed microRNAs (miRNAs) related to PLA2G2A and PLA2G12B in serum were screened; D: The gene expression levels of 6 different miRNA molecules in serum. ICC, cholelithiasis (Ch) and N; E: Receiver operating characteristic (ROC) curves of PLA2G2A and PLA2G12B in serum extracellular vesicles in cholangiocarcinoma (CCA) and N groups; F: ROC curves of PLA2G2A and PLA2G12B in serum extracellular vesicles in CCA and PSC groups; G: ROC curves of PLA2G2A and PLA2G12B in urine extracellular vesicles in CCA and N groups; H: ROC curves of miRNAs were expressed differently in the ICC group and N group; I: ROC curves of miRNAs expressed differently in the ICC group and Ch group. CCA: Cholangiocarcinoma; PSC: Primary sclerosing cholangitis; EVs: Extracellular vesicles; AUC: Area under the curve; ICC: Intrahepatic cholangiocarcinoma.